Posted by Michael Wonder on 14 Oct 2016
TGA publishes AusPAR for Entresto
14 October 2016 - The TGA has published an AusPAR for Novartis' Entresto.
The TGA approved Entresto on 15 January 2016 for use by adult patients for the treatment of chronic heart failure (NYHA Class II-IV) with reduced ejection fraction.
